NCT00753883View on ClinicalTrials.gov

Ezetrol Post-Marketing Study

PHASE4CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

May 31, 2008

Conditions

Hyperlipidemia

Interventions

DRUG

simvastatin

simvastatin 20 mg/QD for 6 Weeks.

DRUG

Ezetimibe

Ezetimibe 10 mg/QD for 8 weeks.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00753883 - Ezetrol Post-Marketing Study | Biotech Hunter | Biotech Hunter